(Q35143044)

6 August 2017

1 reference

title

Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan (English)

1 reference

6 August 2017

Caio M Rocha Lima

1

1 reference

6 August 2017

Alberto Chiappori

series ordinal

2

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

40

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

229-236

1 reference

6 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Epidemiology of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Current standards of care in small-cell and non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Management of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Chemotherapy as treatment of primary and recurrent small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan: a review of its efficacy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Chemotherapy for brain metastases of lung cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan--a new treatment option in the therapy of brain metastases of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900039-4

7 January 2021

10.1016/S0169-5002(03)00039-4

Identifiers

DOI

1 reference

6 August 2017

1 reference